Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission
Cooperative Group
Australasian Leukaemia and Lymphoma Group (ALLG)
Summary
Eligible participants will be randomised to receive Molibresib (investigational product) at recommended dose of 60mg daily, taken orally 28 days per (28 day) cycle; or standard of care, which is generally observation.